[cthalupa]

A huge chunk of Novo losing it's valuation is the fact that Eli Lilly is absolutely destroying them on the next generations of these. Tirzepatide is better than Semaglutide, and Retatrutide is better than Tirzepatide. Mazdutide looks to be a particularly good fit for Asia for a variety of reasons. And from Novo, Cagrilintide/CagriSema look to be a bust. Rybelsus is a bust.

Other "newcomers" in the GLP-1 space are also showing more promise than what Novo has in the pipeline. Boehringer Ingelheim has Survodutide in the pipeline as well, along with plenty of others.

They're the least interesting game in town when it comes to the incretin mimetics at this point.